Spectrum Pharmaceuticals Provides Update on ROLVEDON (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results

31.01.2023 - Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology, today announced business highlights and preliminary ROLVEDON net sales for the quarter and year ended December 31, 2022. Business ... Seite 1

Related Keywords

,Spectrum Pharmaceuticals ,Tom Riga ,Chief Executive Officer ,Regarding Forward Looking ,